Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.43 |
| ▸ | DTYMK | P23919 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | CFTR | P13569 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | CKS1B | P61024 | 1/20 | 0.38 |
| ▸ | SKP1 | P63208 | 1/20 | 0.38 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5748387 | 0.85 | POLB (0.41) | POLBGPR119DTYMKMAP4K4GBA1 | |
| SCHEMBL5747116 | 0.85 | POLB (0.41) | POLBGPR119DTYMKMAP4K4GBA1 | |
| SCHEMBL5748603 | 0.85 | POLB (0.41) | POLBGPR119DTYMKMAP4K4GBA1 | |
| SCHEMBL633008 | 0.84 | USP30 (0.42) | POLBGPR119DTYMKGRM5PDE10A | |
| SCHEMBL5801156 | 0.82 | POLB (0.39) | POLBGPR119DTYMKMAP4K4GRM5 | |
| SCHEMBL5509551 | 0.78 | ALDH1A1 (0.42) | POLBGPR119 | |
| SCHEMBL5747118 | 0.76 | OPRK1 (0.38) | ACHEGRM5 | |
| SCHEMBL23360226 | 0.74 | ALDH1A1 (0.51) | POLBGPR119DTYMK | |
| SCHEMBL20223124 | 0.73 | MAP4K4 (0.58) | POLBGPR119DTYMKMAP4K4GBA1 | |
| SCHEMBL5363583 | 0.73 | MAP4K4 (0.52) | POLBGPR119MAP4K4GBA1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1343780-B1 | PIPERAZINE DERIVATIVES FOR TREATMENT OF BACTERIAL INFECTIONS | SMITHKLINE BEECHAM PLC (GB) | 2006-09-20 | — | — | EP | disclosed |
| US-20040077655-A1 | Piperazine derivatives for treatment of bacterial infections | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-04-22 | — | — | US | disclosed |
| EP-1343780-A1 | PIPERAZINE DERIVATIVES FOR TREATMENT OF BACTERIAL INFECTIONS | SMITHKLINE BEECHAM PLC (GB) | 2003-09-17 | — | — | EP | disclosed |
| WO-2002050061-A1 | PIPERAZINE DERIVATIVES FOR TREATMENT OF BACTERIAL INFECTIONS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077655-A1 | Piperazine derivatives for treatment of bacterial infections | MYD88, THPO, PIGO | POLB 421/4885GPR119 3182/4885DTYMK 1388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.